Tirzepatide + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Overweight
Conditions
Overweight, Obesity
Trial Timeline
Sep 20, 2023 → May 1, 2026
NCT ID
NCT06047548About Tirzepatide + Placebo
Tirzepatide + Placebo is a phase 3 stage product being developed by Eli Lilly for Overweight. The current trial status is active. This product is registered under clinical trial identifier NCT06047548. Target conditions include Overweight, Obesity.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06962280 | Phase 3 | Active |
| NCT06914895 | Phase 3 | Active |
| NCT06191848 | Approved | Recruiting |
| NCT06439277 | Phase 3 | Recruiting |
| NCT05708859 | Approved | Recruiting |
| NCT06075667 | Phase 3 | Active |
| NCT06037252 | Phase 2 | Active |
| NCT06047548 | Phase 3 | Active |
| NCT05963022 | Phase 3 | Completed |
| NCT05536804 | Phase 2 | Active |
| NCT05696847 | Phase 1 | Completed |
| NCT05691712 | Phase 3 | Completed |
| NCT05556512 | Phase 3 | Active |
| NCT05412004 | Phase 3 | Completed |
| NCT05024032 | Phase 3 | Completed |
| NCT04235959 | Phase 1 | Completed |
| NCT04081337 | Phase 1 | Completed |
| NCT04050553 | Phase 1 | Completed |
| NCT04184622 | Phase 3 | Completed |
| NCT04166773 | Phase 2 | Completed |
Competing Products
20 competing products in Overweight